Kim Papp

Research interests

Publications

• Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

  The Lancet · 2021 · 10.1016/s0140-6736(21)00588-2

• Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

  The Lancet · 2018 · https://doi.org/10.1016/s0140-6736(18)31713-6

• Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

  New England Journal of Medicine · 2017 · 10.1056/nejmoa1607017

• Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

  The Lancet · 2017 · 10.1016/s0140-6736(17)31279-5

• Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)31191-1

• Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

  Journal of the American Academy of Dermatology · 2017 · https://doi.org/10.1016/j.jaad.2016.11.041

• Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

  New England Journal of Medicine · 2016 · 10.1056/nejmoa1504370

• Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1512711

• A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis

  British Journal of Dermatology · 2016 · 10.1111/bjd.14493

• Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial

  The Lancet · 2015 · https://doi.org/10.1016/s0140-6736(15)00388-8

• Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials

  British Journal of Dermatology · 2015 · https://doi.org/10.1111/bjd.14018

• Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

  Journal of the American Academy of Dermatology · 2015 · 10.1016/j.jaad.2015.03.049

• Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1503824

• Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

  The Lancet · 2015 · https://doi.org/10.1016/s0140-6736(15)60125-8

• Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1314258

• Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics

  Journal of the American Academy of Dermatology · 2013 · 10.1016/j.jaad.2013.07.023

• Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

  New England Journal of Medicine · 2012 · 10.1056/nejmoa1109017

• Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty‐four–week efficacy and safety results of a randomized, placebo‐controlled study

  Arthritis & Rheumatism · 2009 · 10.1002/art.24403

• Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

  The Lancet · 2008 · https://doi.org/10.1016/s0140-6736(08)60725-4

• Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

  The Lancet · 2008 · https://doi.org/10.1016/s0140-6736(08)60726-6

• Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

  Journal of the American Academy of Dermatology · 2007 · 10.1016/j.jaad.2007.09.010

• Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)

  British Journal of Dermatology · 2007 · 10.1111/j.1365-2133.2007.08315.x

• A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis

  Journal of the American Academy of Dermatology · 2006 · 10.1016/j.jaad.2006.07.017

• A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

  British Journal of Dermatology · 2005 · 10.1111/j.1365-2133.2005.06688.x

• Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

  The Lancet · 2005 · https://doi.org/10.1016/s0140-6736(05)67566-6

• Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial

  The Lancet · 2005 · https://doi.org/10.1016/s0140-6736(05)67763-x

Current projects

No projects listed.